Docivyx Generic: When Will Generic Docetaxel Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Docivyx Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? March 2036 About 9.5 years away Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet
- When does the last patent end? March 2036 Its only patent listed with the FDA
- Can you buy a generic today? Yes 18 companies list one
It already is. A generic docetaxel is listed for sale by 18 companies, so ask your pharmacy whether it can fill your prescription with one.
Why March 2036?
It is when Docivyx’s patent 10,398,785 ends. That patent covers the product’s formulation, and once it ends, generics can go on sale as soon as the FDA approves them. We rate it probable: more likely than not, but it can still move.
What should I do now?
Ask your pharmacy whether it can fill your prescription with a generic. It may look different from Docivyx, but the active ingredient, strength and form are the same. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Docivyx by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- None filed yet No filers on record
- Brand sales
- $202M a yearBig seller
- FDA approved 2022 November 2022 FDA Orange Book
- Patents listed 1 last runs to March 2036 FDA Orange Book
- Medicare Part D spent $84.8K in 2025 CMS Part D Spending by Drug
- Medicaid prescriptions 2,805 in the last four reported quarters, $11.1M CMS Medicaid drug utilization, to Q1 2026
Docivyx’s Road to a Generic
Docivyx has had the market to itself since the FDA approved it in November 2022 (Avyxa Holdings LLC). Its one listed patent runs to March 2036.
The first generic of Docivyx is expected in March 2036.
Why that month: patent 10,398,785, on the product’s formulation, ends then.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Docivyx Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Docivyx’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patent 10,398,785, which ends in March 2036, the month the first generic is expected.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 10,398,785 Sets the expected month of generic availability | The product’s formulation | March 2036 | Active |
Source: FDA Orange Book, application 215813. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Docetaxel
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No company is recorded as having applied to the FDA to make a generic Docivyx yet.
Approved by the FDA
Not yet. The FDA has not approved a generic docetaxel. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Yes. A generic docetaxel is listed for sale by 18 companies. Ask your pharmacy whether it can fill your prescription with it.
Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Amneal Pharmaceuticals LLC, Armas Pharmaceuticals Inc., AuroMedics Pharma LLC, Baxter Healthcare Corporation and 12 more
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Docivyx Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for Docivyx, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Docivyx
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Docivyx, before manufacturer rebates.
- $71.2K
- January to March 2026, the latest CMS has posted
About $5,474 per prescription fill - $84.8K
- 2025, the whole year
About $7,069 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $71,165 | – | $5,474.20 |
| 2025 | $84,834 | – | $7,069.47 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Docivyx only, so no generic is counted in it. What CMS says it is used for: This medication is used to treat cancer (such as breast, lung, prostate, stomach, and head/neck cancer). Docetaxel is a member of a family of drugs called taxanes.
Medicaid Prescriptions by Quarter
2,805 prescriptions in the four quarters to Q1 2026, $11.1M paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q1 2026 | 601 | $2,218,182 |
| Q4 2025 | 638 | $2,527,087 |
| Q3 2025 | 853 | $3,543,117 |
| Q2 2025 | 713 | $2,818,492 |
| Q1 2025 | 517 | $2,142,293 |
Source: CMS Medicaid State Drug Utilization Data, over Docivyx’s own package codes.
Docivyx Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 160MG/16ML (10MG/ML) | Solution | Intravenous | November 2022 | Prescription reference product |
| 20MG/2ML (10MG/ML) | Solution | Intravenous | November 2022 | Prescription reference product |
| 80MG/8ML (10MG/ML) | Solution | Intravenous | November 2022 | Prescription reference product |
Source: FDA Orange Book, Avyxa Holdings LLC. Listed for sale today by Avyxa Pharma, LLC (FDA NDC Directory).
Docivyx NDC Codes and Packages
Each Docivyx package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 83831-0103-16 | DOCETAXEL 160 mg/16mL injection, solution | vial of 16 mL | Avyxa Pharma, LLC |
| 83831-0101-02 | DOCETAXEL 20 mg/2mL injection, solution | vial of 2 mL | Avyxa Pharma, LLC |
| 83831-0102-08 | DOCETAXEL 80 mg/8mL injection, solution | vial of 8 mL | Avyxa Pharma, LLC |
Source: the FDA NDC Directory, current listings only. Only packages sold under Docivyx’s own FDA approval (NDA 215813) are listed, never a generic. Some codes belong to companies that repackage Docivyx: it is the same medicine in a different package.
What a Generic Docivyx Means for You
Nothing Changes Until It Is in Pharmacies
A generic is listed for sale now, so your pharmacy may already be able to fill your prescription with it.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Questions people ask about Docivyx
Is there a generic for Docivyx right now?
Yes. The FDA NDC Directory lists a generic docetaxel from 18 companies. Ask your pharmacy whether it can fill your prescription with it.
When will Docivyx go generic?
It already has. The FDA NDC Directory lists a generic docetaxel from 18 companies, so ask your pharmacy whether it can fill your prescription with one.
Will generic docetaxel be the same as Docivyx?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. No company is recorded as having applied to the FDA to make one yet, and a single company usually brings only a modest drop.
Has the FDA approved a generic Docivyx?
Not yet. The FDA Orange Book lists no approved generic version of Docivyx.
When does the Docivyx patent expire?
One patent is listed for Docivyx in the FDA Orange Book; it runs to March 2036. The one behind the expected month is patent 10,398,785, which ends in March 2036. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (March 2036) weighs all of that.
Changes to This Projection
- First generic expected March 2036 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- BronchitolMannitolOctober 2027
- TivicayDolutegravir SodiumDuring 2028
- LodocoColchicineNovember 2033
- FlyrcadoFlurpiridaz F 18December 2036
- Potassium PhosphatesPotassium PhosphatesApril 2039
- YupelriRevefenacinApril 2039
About Docivyx
- Generic name docetaxel
- How it is taken Into a vein (IV)
- Company Avyxa Holdings LLC
- More drugs Brand-name drugs starting with D
- Have a question? A pharmacist answers, free. Ask about Docivyx
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.